磷脂酰肌醇蛋白聚糖3在肝癌治疗中的应用进展

任志忠; 张跃伟

doi:10.3969/j.issn.1001-5256.2017.07.037

磷脂酰肌醇蛋白聚糖3在肝癌治疗中的应用进展

DOI: 10.3969/j.issn.1001-5256.2017.07.037

遵义医学院

基金项目:

国家自然科学基金项目(81571783)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1854
- HTML全文浏览量: 21
- PDF下载量: 450
- 被引次数: 0
出版历程
- 出版日期: 2017-07-20

Advances in the application of GPC3 in treatment of liver cancer

Zunyi Medical University

Research funding:

摘要

摘要: 肝癌是常见恶性肿瘤之一,传统的肝癌治疗方法各自存在局限性。磷脂酰肌醇蛋白聚糖(GPC)3是一种细胞膜表面的硫酸乙酰肝素蛋白多糖,参与调控个体发育、细胞增殖和分化等过程,是一种肝癌特异性癌胚抗原。GPC3在肝癌发生、发展中的作用机制已成为研究热点。GPC3不仅在肝癌诊断方面有独特价值,在肝癌治疗方面更有重要作用。介绍了应用GPC3瘤苗、GPC3抗体、GPC3基因及靶向等治疗手段,为肝癌治疗提供了新的思路。
- 肝肿瘤 /
- 磷脂酰肌醇蛋白聚糖类 /
- 治疗 /
- 综述
Abstract: Liver cancer is one of the most common malignant tumors in the world, and traditional liver cancer treatment methods have their own limitations.Glypican-3 (GPC3) is a cell-surface heparan sulfate proteoglycan and is involved in the regulation of individual development and cell proliferation and differentiation.It is also a hepatoma-specific carcinoembryonic antigen.The mechanism of action of GPC3 in the development and progression of liver cancer has become a hot research topic.GPC3 not only has a unique value in the diagnosis of liver cancer, but also plays an important role in the treatment of liver cancer.This article also introduces the application of GPC3-derived tumor vaccines, GPC3 antibodies, GPC3 gene therapy, and targeted therapy and brings new ideas for the treatment of liver cancer.
- liver neoplasms /
- glypicans /
- therapy /
- review

HTML全文

参考文献(32)

[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]XU F, TANG B, DAI CL, et al.Research advances in risk factors for surgical site infection after liver cancer resection[J].Clin J Med Offic, 2016, 44 (8) :872-874. (in Chinese) 徐锋, 唐斌, 戴朝六, 等.肝癌切除术后手术部位感染危险因素研究新进展[J].临床军医杂志, 2016, 44 (8) :872-874.

[3]PILIA G, HUGHES-BENZIE RM, MACKENZIE A, et al.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome[J].Na Genet, 1996, 12 (3) :241-247.

[4]HUYNH H, NGO VC, KOONG HN, et al.AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC) [J].J Hepatol, 2010, 52 (1) :79-87.

[5]HUANG H, LIN J, RUAN J, et al.MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3[J].FEBS Lett, 2012, 586 (6) :884-891.

[6]YU DD, DONG ZZ, YAO M, et al.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA[J].Tumor Biol, 2013, 34 (2) :661-668.

[7]CHEN J, YAO M, YAO DF, et al.Role of glypican-3 signaling pathways and therapeutic potential in hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :77-80. (in Chinese) 陈洁, 姚敏, 姚登福, 等.磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗[J].临床肝胆病杂志, 2013, 29 (1) :77-80.

[8]YANG J, YAO M, WANG L, et al.Synergistic effect of intervention of glypican-3 gene transcription combined with antitumor drugs in inhibiting hepatoma cell proliferation[J].J Clin Hepatol, 2016, 32 (12) :2347-2352. (in Chinese) 杨婕, 姚敏, 王理, 等.干预磷脂酰肌醇蛋白多糖3基因转录联合抗肿瘤药物抑制肝癌细胞增殖的协同作用[J].临床肝胆病杂志, 2016, 32 (12) :2347-2352.

[9]YAO M, WANG L, DONG Z, et al.Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy[J].Tumour Biol, 2014, 35 (6) :5857-5868.

[10]WU YL, WANG YL, MU H, et al.Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine induced killer cells against hepatocellular carcinoma cells[J].Mol Med Rep, 2015, 11 (5) :3361-3367.

[11]PAN Z, CHEN C, LONG H, et al.Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis[J].Mol Med Rep, 2013, 7 (3) :969-974.

[12]SAWADA Y, YOSHIKAWA T, NOBUOKA D, et al.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma:immunologic evidence and potential for improving overall survival[J].Clin Cancer Res, 2012, 18 (13) :3686-3696.

[13]SAWADA Y, YOSHIKAWA T, FUJII S, et al.Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination[J].Hum Vaccin Immunotherapeutics, 2013, 9 (6) :1228-1233.

[14]TADA Y, YOSHIKAWA T, SHIMOMURA M, et al.Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide[J].Int J Oncol, 2013, 43 (4) :1019-1026.

[15]NOBUOKA D, MOTOMURA Y, SHIRAKAWA H, et al.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3peptide-specific cytotoxic T lymphocytes[J].Int J Oncol, 2012, 40 (1) :63-70.

[16]YORITA K, TAKAHASHI N, TAKAI H, et al.Prognostic significance of circumferential cell surface immunoreactivity of glypican-3in hepatocellular carcinoma[J].Liver Int, 2011, 31 (1) :120-131.

[17]ISHIGURO T, SUGIMOTO M, KINOSHITA Y, et al.Anti-glypican 3 antibody as potential agent for huaman liver cancer[J].Cancer Res, 2008, 68 (23) :9832-9838.

[18]ANDREW X, PHILIP J, ANTHONY B, et al.First-in-man phase Istudy of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2013, 19 (4) :920-928.

[19]IKEDA M, OHKAWA S, OKUSAKA T, et al.Japanese phase Istudy of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma[J].Cancer Sci, 2014, 10 (4) :345-348.

[20]FENG MQ, GAO W, WANG RQ, et al.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma[J].Proc Natl Acad Sci U S A, 2013, 110 (12) :1083-1091.

[21]GAO W, TANG ZW, ZHANG YF, et al.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis[J].Nat Commun, 2015, 6:6536.

[22]HANAOKA H, NAGAYA T, SATO K, et al.Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy[J].Mol Pharm, 2015, 12 (6) :2151-2157.

[23]GAO W, KIM H, HO M.Human monoclonal antibody targeting the heparan sulfate chains of Glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells[J].PLo SOne, 2015, 10 (9) :7664-7669.

[24]GAO W, KIM H, FENG M, et al.Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy[J].Hepatology, 2014, 60 (2) :576-587.

[25]FENG M, HO M.Glypican-3 antibodies:a new therapeutic target for liver cancer[J].FEBS Letters, 2014, 588 (2) :377-382.

[26]HANAOKA H, NAKAJIMA T, SATO K, et al.Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel[J].Nanomedicine (Lond) , 2015, 10 (7) :1139-1147.

[27]MIAO HL, LEI CJ, QIU ZD, et al.MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3[J].Hepatol Res, 2014, 4 (3) :338-348.

[28]XU MZ, YAO TJ, LEE NP, et al.Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma[J].Cancer, 2009, 115 (19) :4576-4585.

[29]MIAO H, LEI CJ, WEN JY, et al.Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through downregulation of YAP[J].J Cell Biochem, 2013, 114 (3) :625-631.

[30]MAGISTRI P, LEONARD SY, TANG CM, et al.The glypican 3hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling[J].J Surg Res, 2014, 18 (2) :377-385.

[31]YANG XX, MA H.Research advances in tumor markers of hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (4) :811-855. (in Chinese) 杨霄霄, 马红.肝细胞癌肿瘤标志物的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :811-855.

[32]YAO M, YANG Y, YAO DF, et al.Clinical value of circulating peripheral blood mononuclear cell glypican-3 mRNA and alpha fetoprotein for diagnosing and monitoring metastasis of hepatocellular carcinoma[J].J Clin Hepatol, 2012, 28 (10) :777-781. (in Chinese) 姚敏, 杨燕, 姚登福, 等.循环血单核细胞GPC3 mRNA和甲胎蛋白对肝癌诊断与转移监测的潜在价值[J].临床肝胆病杂志, 2012, 28 (10) :777-781.

施引文献

资源附件(0)

访问统计